US 12,012,457 B1
IL23R binding molecules and methods of use
Robert Kastelein, Menlo Park, CA (US); Patrick J. Lupardus, Menlo Park, CA (US); and Deepti Rokkam, Menlo Park, CA (US)
Assigned to Synthekine, Inc., Menlo Park, CA (US)
Appl. No. 18/017,065
Filed by Synthekine, Inc., Menlo Park, CA (US)
PCT Filed Aug. 5, 2021, PCT No. PCT/US2021/044835
§ 371(c)(1), (2) Date Jan. 19, 2023,
PCT Pub. No. WO2022/032023, PCT Pub. Date Feb. 10, 2022.
Claims priority of provisional application 63/135,884, filed on Jan. 11, 2021.
Claims priority of provisional application 63/078,745, filed on Sep. 15, 2020.
Claims priority of provisional application 63/061,562, filed on Aug. 5, 2020.
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 2317/569 (2013.01)] 42 Claims
 
1. A 1IL23R binding molecule that specifically binds to the extracellular domain of IL23R, wherein the IL23R binding molecule comprises a single domain antibody (sdAb), wherein the sdAb comprises a complementary determining region 1 (CDR1), a CDR2, and a CDR3 as shown in a row of the table below:
 
CDR1 CDR2 CDR3
 
YTYCSYDMS AFNSDGTTSYADSVKG DPHVQSSGGYCPPY
(SEQ ID NO: 21) (SEQ ID NO: 22) (SEQ ID NO: 23)
 
YTYCSYDMS SFNSDGSTSYADSVKG DPHADWGAPCGGDY
(SEQ ID NO: 24) (SEQ ID NO: 25) (SEQ ID NO: 26)
 
YTYCSYDMS AIASDGSTSYADSLKG DPHVQSSGGYCPPY
(SEQ ID NO: 33) (SEQ ID NO: 34) (SEQ ID NO: 35)
 
YTYCSYDMG SINSDGTTSYADSVKG DPQTRPGKPCADY
(SEQ ID NO: 36) (SEQ ID NO: 37) (SEQ ID NO: 38)
 
YTYCSYDMK GIDSDGSISYADSVKG EGTIPVGACPNY
(SEQ ID NO: 42) (SEQ ID NO: 43) (SEQ ID NO: 44)
 
YTYCSYDMS SINSDGTTSYADSVKG DPQTRPGKPCADY
(SEQ ID NO: 45) (SEQ ID NO: 46) (SEQ ID NO: 47)
 
YTYCSYDMT AIDSDGSTSYADSVKG DPIATISRRCDSY
(SEQ ID NO: 51) (SEQ ID NO: 52) (SEQ ID NO: 53)
 
YTYCSYDMK AIDSDGSTSYADSVKG EGTIPVGVCPNY
(SEQ ID NO: 57) (SEQ ID NO: 58) (SEQ ID NO: 59)
 
YTYCSYDMK AIDSDGSTSYADSVKG EGTVPVGVCPNY
(SEQ ID NO: 60) (SEQ ID NO: 61) (SEQ ID NO: 62)
 
YTSCSYDMS AIHSDGTTSYADSMKG DPNYSDHVCPPY
(SEQ ID NO: 75) (SEQ ID NO: 76) (SEQ ID NO: 77).